MedTrace Logo

Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening

NCT06512311 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2026-04-14

No results posted yet for this study

Summary

Patient derived cell line (PDC) -based drug screening will be applied to formulate a personalized treatment approach.

Conditions

Interventions

DIAGNOSTIC_TEST

CBMed Drug Screening Plattform

The main devices used within the drug screening process are purchased from PerkinElmer, Liconic Instruments, BioTek and Beckman Coulter Diagnostics.

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-10
Primary Completion
2030-12-31
Completion
2031-12-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06512311 on ClinicalTrials.gov